Impact of Clostridioides difficile infection in patients admitted with ulcerative colitis

References

• Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211–1221.
   PubMed Web of Science ®Google Scholar
• Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol. 2016;14(10):609–620.
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against Toxin A. N Engl J Med. 2000;342(6):390–397.
   PubMed Web of Science ®Google Scholar
• Del Prete R, Ronga L, Addati G, et al. Clostridium difficile. A review on an emerging infection. Clin Ter. 2019;170:41–47.
   Web of Science ®Google Scholar
• Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206–216.
   PubMed Web of Science ®Google Scholar
• Kukla M, Adrych K, Dobrowolska A, et al. Guidelines for Clostridium difficile infection in adults. Prz Gastroenterol. 2020;15(1):1–21.
   PubMed Web of Science ®Google Scholar
• De Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome an intregrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(12):739–749.
   PubMed Web of Science ®Google Scholar
• Da Silva BC, Castro A, Rocha R, et al. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20(28):9458–9467.
   PubMed Web of Science ®Google Scholar
• Puig L, Ruiz de Morales JG, Dauden E, et al. La prevalencia de diez enfermedades inflamatorias inmunomediadas (IMID) en españa. Rev Españ Sal Públ. 2019;93:1–14.
   Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670.
   PubMed Web of Science ®Google Scholar
• Regnault H, Bourrier A, Lalande V, et al. Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. Dig Liver Dis. 2014;46(12):1086–1092.
   PubMedGoogle Scholar
• Sokol H, Lalande V, Landman C, et al. Clostridium difficile infection in acute flares of inflammatory bowel disease: a prospective study. Dig Liver Dis. 2017;49(6):643–646.
   PubMedGoogle Scholar
• Beniwal-Patel P, Stein DJ, Munoz-Price LS. The juncture between Clostridioides difficile infection and inflammatory bowel diseases. Clin Infect Dis. 2019;69(2):366–372.
   PubMed Web of Science ®Google Scholar
• Singh H, Nugent Z, Yu BN, et al. Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153(2):430–438.e2.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7(2):107–112.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Guzmán-Pérez R, Gainer V, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(7):789–795.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Mukewar S, Venkatesh PG, et al. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis. 2012;6(3):330–336.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–983.
   PubMed Web of Science ®Google Scholar
• Ricciardi R, Ogilvie JW Jr, Roberts PL, et al. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum. 2009;52(1):40–45.
   PubMed Web of Science ®Google Scholar
• Parragi L, Fournier N, Zeitz J, et al.; Swiss IBD Cohort Study Group. Colectomy rates in ulcerative colitis are low and decreasing: 10-year follow-up data from the Swiss IBD cohort study. J Crohns Colitis. 2018;12(7):811–818.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443–1450.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–1548.
   PubMed Web of Science ®Google Scholar
• Bossuyt P, Verhaegen J, Van Assche G, et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3(1):4–7.
   PubMed Web of Science ®Google Scholar
• Kariv R, Navaneethan U, Venkatesh PGK, et al. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohns Colitis. 2011;5(1):34–40.
   PubMed Web of Science ®Google Scholar
• Razik R, Rumman A, Bahreini Z, et al. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016;111(8):1141–1146.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu H, Xu T, et al. Case-control study of inflammatory bowel disease patients with and without Clostridium difficile infection and poor outcomes in patients coinfected with C. difficile and cytomegalovirus. Dig Dis Sci. 2018;63(11):3074–3083.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a metaanalysis. Clin Gastroenterol Hepatol. 2012;10(3):225–233.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30(3):253–264.
   PubMed Web of Science ®Google Scholar
• Furuya-Kanamori L, Stone JC, Clark J, et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and metaanalysis. Infect Control Hosp Epidemiol. 2015;36(2):132–141.
   PubMed Web of Science ®Google Scholar
• D’Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol. 2017;23(27):4986–5003.
   PubMed Web of Science ®Google Scholar
• Albarrak AA, Romana BS, Uraz S, et al. Clostridium difficile infection in inflammatory bowel disease patients. Endocr Metab Immune Disord Drug Targets. 2019;19(7):929–935.
   PubMed Web of Science ®Google Scholar
• Hibiya S, Matsuyama Y, Fujii T, et al. 5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2021;53(1):103–113.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Margalit M, Bossuyt P, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis. 2010;4(2):194–198.
   PubMed Web of Science ®Google Scholar
• Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(4):428–441.
   PubMed Web of Science ®Google Scholar